Volume : 12, Issue : 01, January – 2025
Title:
PREPARATION AND EVALUATION OF CLOTRIMAZOLE EMULGEL
Authors :
A. Lakshmi Usha, A.V.S. Bhavani, K. Vijay Vardhan, B. Kusumanjali, M. Chayanica, L. Satish
Abstract :
The present study aims to formulate, evaluate, and report the current potential and future scope of topical formulation for becoming an effective delivery system for poorly water-soluble drugs. The drug selected for this study was Clotrimazole, a potent drug with the major drawback of a short elimination half-life (2hrs), which is used for the treatment of fungal infections topically. Clotrimazole emulgel formulations were prepared using clove oil as the lipid phase, Span 80 as surfactant, and Polyethylene glycol as co-surfactant. The effect of polymer concentration on drug release was studied. Clotrimazole being a BCS class II drug with low solubility and high permeability was initially incorporated in the oily phase of emulsion and O/W emulsion was formulated. This formulated emulsion was incorporated into the gelling agent carbopol and emulgel was obtained. A total of six formulations were prepared, each one of oil with different ratios of surfactant and co-surfactant (1:2, 2:1 formulations) were prepared. From the study, it was concluded that the formulations prepared with minimum concentration of gel base and maximum concentration of emulgel enhanced the drug release rate. The optimized formulations F5 showed good stability, thereby enhancing the drug release rate leading to improved bioavailability of Clotrimazole. The optimized formulations F5 showed 67.31% of drug release in 5 hours and a maximum of 96.15% of drug release was achieved in 8 hours.
Cite This Article:
Please cite this article in press A.Lakshmi Usha et al., Preparation And Evaluation Of Clotrimazole Emulgel.,Indo Am. J. P. Sci, 2025; 12 (01).
Number of Downloads : 10
References:
1. Sigmundsdotti H. Improving topical treatment for skin diseases. Trends in pharmacological science. 2010; 31 (6): 239-245.
2. Dawson AL, Dellavalle RP, Elston DM. Infectious skin diseases: a review and needs assessment. Dermatologic clinics. 2012;30(1): 141-151.
3. Kumar PM, Patel MR, Patel KR, Patel NM. Emulgels: a novel approach to topical drug delivery. Internation journal of university pharm bio Sciences.2013; 2(1): 134-148.
4. Gungor S, Erdal MS, Aksu B, New formulation strategies in topical antifungal therapy. Journal of cosmetics, dermatological sciences, and applications. 2013 Jan 9; 3(01):56.
5. Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skin: theory and in vitro experimental measurement. Americal institute of chemical engineering journal.1975 Sep; 21(5):985-996.
6. Ellabib MS, Khalifa Z, Kavanagh K. Dermatophytes and other fungi associated with skin mycoses in Tripoli, Libya. Mycoses. 2002 Apr 1; 45(3-4): 101-104.
7. Dhiman S, Singh TG, Rehni AK. Transdermal patches: A recent approach to new drug delivery system. International journal of pharmacy and pharmaceutical science 2011; 3(5): 26-34.
8. Foldvari M. Non-invasive administration of drug through the skin: challenges in the delivery system in design. Pharmaceutical science & technology today. 2000 Dec 1; 3(12):417-425.
9. Mohamed MI. Optimization of chlorophensin emulgel formulation. The American Association Pharmaceutical Science Journal. 2004 Sep 1;6(3):81-87.
10. Alexander A, Dwivedi S, Giri TK, Saraf S, Tripathi DK. Approaches for breaking the barrier of drug permeation through transdermal drug delivery. Journal of controlled release. 2012; 164(1): 26-40.
11. Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery system in dermatology: a review of patient adherence issues. Expert opinion on drug delivery. 2012 Oct 1; 9(10):1263-1271.
12. Alex N. Mwangi et al.., The study designed, formulated, and evaluated meloxicam emulgels as a potential alternative topical treatment option for rheumatism, International Journal of Research Articles, Mumbai, India. 2015; 5(3)61-98.
13. Ayalasomayajula LU, Patro CS, Raul SK. Selection and Characterization of a Nanoemulsion of Poorly Soluble Drug by Applying Box-Behnken Design and Converting it into a Nanoemulgel for Topical Application. International Journal of Pharmaceutical Quality Assurance. 2024;15(1):1-10.
14. Sharm N, Agarwal G, Rana AC, Bhat ZA, Kumar D. A review: transdermal drug delivery system, a tool for novel drug delivery system. Internation Journal of drug delivery and research. 2011;3(1): 70-84.
15. Fisher MC, Henk DA, Briggs CJ, Brownstein JS, Madoff LC, et al., Emerging fungal threats to animal, plant and ecosystem health. Nature. 2012 Apr; 484(7393):186.
16. Jaulim Z, Salmon N, Fuller C. Fungal skin infection: Current approaches to management. Prescriber. 2015 Oct 5; 26(19): 31-35.
17. Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Critical review in microbiology. 2015; 41(3):374-388.
18. Faergemann JN, Pityriasis versicolor, tinea nigra, and piedra. In: Jacobs PH, Nail L. Antifungal drug therapy: a complete guide for the practitioner. New York: Marcel Dekker, 1990:23-30.
19. Ahmad M Eid, Hesham A El-Enshasy, Ramlan Aziz, Nagib A Elmarzugi. Preparation, characterization, and anti-inflammatory activity of Swietenia macrophylla nanoemulgel. Journal Nanomedicinal Auger P, Marquis G, Joly J, Attye A. Epidemiology of tinea pedis in marathon runners: prevalence of occult athlete’s foot. Mycoses. 1993 Jan; 36 (1-2): 35-54.
20. Shah A. Arpan, Kamdar Kamal, Shah Rushabh, Keraliya A. Rajesh., Emulgel: A Topical delivery of Hydrophobic Drugs. Ph Tech Med 2013; 2(5): 370-376.
21. Kumar JR, Muralidharan S, Parasuraman S. Antifungal agents: a new approach for novel delivery systems. Journal and Nanotechnology. 2014; 5(2):1-10.
22. Ayalasomayajula LU, Patro CS, Raul SK. Characterization of Oxiconazole Nanoemulsion Using Box-Behnken Design and Transformation of the Selected Nanoemulsion into Nanoemulgel. Int. J. Pharm. Investigation. 2024;14(3):738-48.